Company profile
REGENXBIO Inc.
NASDAQ:RGNXBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Clemidsogene Lanparvovec | phase2_3 | — | 2 | active |
| Ompenaclid | phase2_3 | — | 1 | active |
| Surabgene Lomparvovec | phase1_2 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02651675 | phase1_2 | terminated | 2016-03-01 | 2020-11-27 | REGENXBIO Inc. | A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) |
| NCT05693142 | phase2_3 | active_not_recruiting | 2023-01-04 | 2026-09-01 | REGENXBIO Inc. | AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD) |
| NCT03566043 | phase2_3 | active_not_recruiting | 2018-09-27 | 2023-11-27 | REGENXBIO Inc. | CAMPSIITE™ RGX-121 Gene Therapy in Subjects With MPS II (Hunter Syndrome) |
| NCT03580083 | phase1_2 | suspended | 2019-04-03 | 2027-07-07 | REGENXBIO Inc. | RGX-111 Gene Therapy in Patients With MPS I |
| NCT04571970 | phase1_2 | completed | 2021-03-11 | 2023-05-09 | REGENXBIO Inc. | RGX-121 Gene Therapy in Children 5 Years of Age and Over With MPS II (Hunter Syndrome) |
FDA applications (0)
No records yet.